Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...